SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Phase 1 Completed 53 enrolled Pediatric Brain Tumor Consortium National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.

Timeline

Start: 2002-01
Primary completion: 2005-09
Completion: 2007-03

Publications

Results Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20;25(21):3137-43. doi: 10.1200/JCO.2006.09.4243.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lonafarnib	Small molecule	70 mg/m2	Oral
Subject	Lonafarnib	Small molecule	90 mg/m2	Oral
Subject	Lonafarnib	Small molecule	115 mg/m2	Oral
Subject	Lonafarnib	Small molecule	150 mg/m2	Oral
Subject	Lonafarnib	Small molecule	200 mg/m2	Oral

SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

Summary

Timeline

Publications

Drugs

Indications